Naphthyridine derivatives as inhibitors of hypoxia inducible factor (hif) hydroxylase

Patent metadata

Field	Value
Publication number	US-2016159796-A1
Application number	US-201615043286-A
Country	US
Kind code	A1
Filing date	Feb 12, 2016
Priority date	Feb 2, 2011
Publication date	Jun 9, 2016
Grant date	—

Abstract

The present disclosure relates to novel compounds, methods, and compositions capable of inhibiting HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF).

First claim

1 - 2 . (canceled)

3 . A compound represented by Formula Ib:

wherein
q is 0 or 1;
R 1 is selected from the group consisting of hydrogen, cyano, halo, hydroxy, alkoxy, amino, acyloxy, aminoacyl, alkyl, cycloalkyl, cycloalkoxy, aryl, aryloxy, heterocycloalkyl, heteroaryloxy, and heteroaryl;
one of Z 3 or Z 4 is —NR 2 — and the other of Z 3 or Z 4 is —C(O)—;
R 2 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, heterocycloalkyl, and heteroaryl;
R 3 and R 4 are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, amino, acyloxy, aminoacyl, cycloalkyl, cycloalkoxy, aryl, aryloxy, heterocycloalkyl, heteroaryloxy, and heteroaryl;
is a single or a double bond;
Y is —NR 6 — or —O—;
n is 1, 2, 3, 4, 5, or 6;
R 5 is selected from the group consisting of hydrogen, acyl, sulfonyl, aminoacyl, oxycarbonyl, alkyl, cycloalkyl, aryl, heterocycloalkyl, and heteroaryl;
R 6 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, heterocycloalkyl, and heteroaryl;
R 7 and R 8 are each independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, heterocycloalkyl, and heteroaryl; or R 7 and R 8 together with the carbon atom to which they are attached form a cycloalkyl, or heterocycloalkyl;
W is selected from the group consisting of R 9 , —C(O)OR 9 , —C(O)NR 6 R 9 , —NR 6 C(O)R 9 , —NR 6 C(O)OR 9 , —NR 6 C(O)NR 6 R 9 , —NR 6 S(O) 2 R 9 , —S(O) 2 NR 6 R 9 , —NR 6 R 9 and —OR 9 ; and
R 9 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, heterocycloalkyl, and heteroaryl; and
further wherein each alkyl, alkoxy, amino, acyloxy, aminoacyl, cycloalkyl, cycloalkoxy, aryl, aryloxy, heterocycloalkyl, heteroaryloxy, and heteroaryl described above for R 1 , R 2 , R 3 , R 4 , R 6 , R 7 , R 8 and R 9 can be optionally substituted with from 1 to 3 R 10 ,
wherein each R 10 is independently selected from the group consisting of alkyl, alkoxy, haloalkyl, haloalkoxy, acyl, acylamino, acyloxy, amino, aminoacyl, aminocarbonylamino, aminothiocarbonylamino, aminocarbonyloxy, aryl, aryloxy, aryloxyaryl, cyano, halogen, hydroxyl, nitro, oxo, thioxo, carboxyl, carboxyl ester, cycloalkyl, thio, alkylthio, arylthio, cycloalkylthio, heteroarylthio, heterocyclicthio, sulfonyl, heteroaryl, heterocyclic, cycloalkoxy, heteroaryloxy, heterocyclyloxy, oxycarbonylamino, oxythiocarbonylamino, —OS(O) 2 -alkyl, —OS(O) 2 -aryl, —OS(O) 2 -heteroaryl, —OS(O) 2 -heterocyclic, —OSO 2 —NR 40 R 40 , —NR 40 S(O) 2 —NR 40 -alkyl, —NR 40 S(O) 2 —NR 40 -aryl, —NR 40 S(O) 2 —NR 40 -heteroaryl, and —NR 40 S(O) 2 —NR 40 -heterocyclic, where each R 40 is independently hydrogen or alkyl; and further wherein each alkyl, alkoxy, aryl, aryloxy, aryloxyaryl, cycloalkyl, alkylthio, arylthio, cycloalkylthio, heteroarylthio, heterocyclicthio, heteroaryl, heterocyclic, cycloalkoxy, heteroaryloxy, or heterocyclyloxy may be additionally substituted with from 1-3 substituents independently alkyl, alkoxy, haloalkyl, haloalkoxy, or halogen;
or a pharmaceutically acceptable salt, single stereoisomer, mixture of stereoisomers, ester, tautomer or prodrug thereof.

4 - 5 . (canceled)

6 . The compound of claim 3 , represented by Formula IIIa:

wherein
R 1 is selected from the group consisting of hydrogen, cyano, halo, hydroxy, alkoxy, amino, acyloxy, aminoacyl, alkyl, cycloalkyl, cycloalkoxy, aryl, aryloxy, heterocycloalkyl, heteroaryloxy, and heteroaryl;
R 2 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, heterocycloalkyl, and heteroaryl;
is a single or a double bond;
R 3 and R 4 are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, amino, acyloxy, aminoacyl, cycloalkyl, cycloalkoxy, aryl, aryloxy, heterocycloalkyl, heteroaryloxy, and heteroaryl;
Y is —NR 6 — or —O—;
n is 1, 2, 3, 4, 5, or 6;
R 6 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, heterocycloalkyl, and heteroaryl;
R 7 and R 8 are each independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, heterocycloalkyl, and heteroaryl; or R 7 and R 8 together with the carbon atom to which they are attached form a cycloalkyl, or heterocycloalkyl;
W is selected from the group consisting of R 9 , —C(O)OR 9 , —C(O)NR 6 R 9 , —NR 6 C(O)R 9 , —NR 6 C(O)OR 9 , —NR 6 C(O)NR 6 R 9 , —NR 6 S(O) 2 R 9 , —S(O) 2 NR 6 R 9 , —NR 6 R 9 and —OR 9 ; and
R 9 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, heterocycloalkyl, and heteroaryl;
further wherein each alkyl, alkoxy, amino, acyloxy, aminoacyl, cycloalkyl, cycloalkoxy, aryl, aryloxy, heterocycloalkyl, heteroaryloxy, and heteroaryl described above for R 1 , R 2 , R 3 , R 4 , R 6 , R 7 , R 8 and R 9 can be optionally substituted with from 1 to 3 R 10 ,
wherein each R 10 is independently selected from the group consisting of alkyl, alkoxy, haloalkyl, haloalkoxy, acyl, acylamino, acyloxy, amino, aminoacyl, aminocarbonylamino, aminothiocarbonylamino, aminocarbonyloxy, aryl, aryloxy, aryloxyaryl, cyano, halogen, hydroxyl, nitro, oxo, thioxo, carboxyl, carboxyl ester, cycloalkyl, thio, alkylthio, arylthio, cycloalkylthio, heteroarylthio, heterocyclicthio, sulfonyl, heteroaryl, heterocyclic, cycloalkoxy, heteroaryloxy, heterocyclyloxy, oxycarbonylamino, oxythiocarbonylamino, —OS(O) 2 -alkyl, —OS(O) 2 -aryl, —OS(O) 2 -heteroaryl, —OS(O) 2 -heterocyclic, —OSO 2 —NR 40 R 40 , —NR 40 S(O) 2 —NR 40 -alkyl, —NR 40 S(O) 2 —NR 40 -aryl, —NR 40 S(O) 2 —NR 40 -heteroaryl, and —NR 40 S(O) 2 —NR 40 -heterocyclic, where each R 40 is independently hydrogen or alkyl; and further wherein each alkyl, alkoxy, aryl, aryloxy, aryloxyaryl, cycloalkyl, alkylthio, arylthio, cycloalkylthio, heteroarylthio, heterocyclicthio, heteroaryl, heterocyclic, cycloalkoxy, heteroaryloxy, or heterocyclyloxy may be additionally substituted with from 1-3 substituents independently alkyl, alkoxy, haloalkyl, haloalkoxy, or halogen;
or a pharmaceutically acceptable salt, single stereoisomer, mixture of stereoisomers, ester, tautomer or prodrug thereof.

7 . The compound of claim 3 , represented by Formula IIIb:

wherein
R 1 is selected from the group consisting of hydrogen, cyano, halo, hydroxy, alkoxy, amino, acyloxy, aminoacyl, alkyl, cycloalkyl, cycloalkoxy, aryl, aryloxy, heterocycloalkyl, heteroaryloxy, and heteroaryl;
R 2 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, heterocycloalkyl, and heteroaryl;
is a single or a double bond;
R 3 and R 4 are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, amino, acyloxy, aminoacyl, cycloalkyl, cycloalkoxy, aryl, aryloxy, heterocycloalkyl, heteroaryloxy, and heteroaryl;
Y is —NR 6 — or —O—;
n is 1, 2, 3, 4, 5, or 6;
R 6 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, heterocycloalkyl, and heteroaryl;
R 7 and R 8 are each independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, heterocycloalkyl, and heteroaryl; or R 7 and R 8 together with the carbon atom to which they are attached form a cycloalkyl, or heterocycloalkyl;
W is selected from the group consisting of R 9 , —C(O)OR 9 , —C(O)NR 6 R 9 , —NR 6 C(O)R 9 , —NR 6 C(O)OR 9 , —NR 6 C(O)NR 6 R 9 , —NR 6 S(O) 2 R

Assignees

• Fibrogen Inc

Inventors

• Ng Danny
• Arend Michael P
• Flippin Lee A

Classifications

• C07D471/04 Primary

  Ortho-condensed systems · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61K31/444

  containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone · CPC title

• A61K31/497

  containing further heterocyclic rings · CPC title

• A61K31/4375

  the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine · CPC title